Top Story

FDA grants orphan drug designation to CRS-207 for mesothelioma

March 27, 2015

The FDA granted orphan drug designation to CRS-207 — a novel immuno-oncology product candidate — for the treatment of patients with malignant pleural mesothelioma, according to a press release from the drug’s manufacturer.

CRS-207 (Aduro Biotech) is intended for use in patients with malignant pleural mesothelioma who have not received prior therapy and who are not eligible for surgical resection.

Susan G. Lakoski, MD, MS In the Journals

Cardiorespiratory fitness levels predict risk for cancer diagnosis, mortality

March 26, 2015
Middle-aged men with a high cardiorespiratory fitness level displayed decreased risks for lung and colon cancers, as well as a decreased risk for cancer-related death if…
Jorge J. Castillo, MD In the Journals

Waldenström’s macroglobulinemia increases risk for secondary malignancies

March 25, 2015
Patients with Waldenström’s macroglobulinemia demonstrated an increased risk for secondary malignancies compared with the general population, according to…
In the Journals

Benefits of surgical resection for small cell lung cancer remain unclear

March 23, 2015
Although surgical resection resulted in reasonable outcomes among well-chosen patients with early-stage small cell lung cancer, use of the treatment approach in this…
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
FDA News

FDA grants orphan drug designation to CRS-207 for mesothelioma

March 27, 2015
The FDA granted orphan drug designation to CRS-207 — a novel immuno-oncology product candidate — for the treatment of patients with…
Susan G. Lakoski, MD, MS In the Journals

Cardiorespiratory fitness levels predict risk for cancer diagnosis, mortality

March 26, 2015
Middle-aged men with a high cardiorespiratory fitness level displayed decreased risks for lung and colon cancers, as well as a decreased risk for…
Jorge J. Castillo, MD In the Journals

Waldenström’s macroglobulinemia increases risk for secondary malignancies

March 25, 2015
Patients with Waldenström’s macroglobulinemia demonstrated an increased risk for secondary malignancies compared with the general…
In the Journals

Benefits of surgical resection for small cell lung cancer remain unclear

March 23, 2015
Although surgical resection resulted in reasonable outcomes among well-chosen patients with early-stage small cell lung cancer, use of the treatment…
Neal E. Ready, MD, PhD In the Journals

Maintenance sunitinib extends PFS in extensive-stage small cell lung cancer

March 17, 2015
Maintenance sunitinib safely and effectively prolonged PFS in patients with small cell lung cancer, according to study results.Neal E. Ready, MD
In the Journals

Despite fewer smokers, poor screening criteria may raise lung cancer mortality

March 11, 2015
The decline in smoking rates will translate to fewer people qualifying for lung cancer screening with low-dose CT, thereby potentially leading to…
Meeting News Coverage

Uveal metastasis from lung cancer has high mortality rate

March 9, 2015
PHILADELPHIA — Uveal metastatic cancer from lung cancer had a high globe salvage rate but a poor systemic prognosis, according to a study presented…
In the Journals

EGFR L858R mutation in circulating free DNA linked to NSCLC outcomes

March 9, 2015
A liquid biopsy approach efficiently assessed EGFR mutations in the circulating free DNA of blood samples from patients with non–small cell…
In the Journals

Patient characteristics linked to degree of family involvement in treatment decisions

March 5, 2015
A majority of patients recently diagnosed with lung or colorectal cancers chose to include family members in treatment-related decisions, according…
FDA approvals

FDA expands approval of Opdivo for advanced squamous NSCLC

March 4, 2015
The FDA today expanded the existing indication of nivolumab to include patients with metastatic squamous non–small cell lung cancer with…
More Headlines »
morganatic-roan
morganatic-roan